Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.60 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.60 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.60 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.47 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18347984 | 1.00 | DPP4 (0.60) | DPP4DPP8DPP9DPP7KCNH2 | |
| SCHEMBL18347948 | 1.00 | DPP4 (0.60) | DPP4DPP8DPP9DPP7KCNH2 | |
| SCHEMBL2739926 | 0.90 | DPP4 (0.51) | DPP4DPP8DPP9DPP7KCNH2 | |
| SCHEMBL2739929 | 0.87 | MEN1 (0.48) | DPP4DPP8DPP9DPP7CHRNB2 | |
| SCHEMBL13819928 | 0.85 | CHRNB2 (0.57) | DPP4DPP8DPP9DPP7KCNH2 | |
| SCHEMBL14655488 | 0.84 | DPP4 (0.66) | DPP4DPP8DPP9DPP7KCNH2 | |
| SCHEMBL14655516 | 0.84 | DPP4 (0.66) | DPP4DPP8DPP9DPP7KCNH2 | |
| SCHEMBL30335002 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9DPP7KCNH2 | |
| SCHEMBL5396145 | 0.82 | DPP4 (0.46) | DPP4DPP8DPP9DPP7KCNH2 | |
| SCHEMBL21028179 | 0.82 | CHRNB2 (0.46) | DPP4DPP8DPP9DPP7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022253311-A1 | HPK1 INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-10745356-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. | 2019-09-19 | — | — | US | disclosed |
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9115096-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-8247565-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-7345178-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | DPP4 1318/4885DPP8 3189/4885DPP9 2218/4885 |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | DPP4 1525/4885DPP8 1232/4885DPP9 1080/4885 |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | DPP4 1525/4885DPP8 1232/4885DPP9 1080/4885 |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | DPP4 1992/4885DPP8 1270/4885DPP9 1354/4885 |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | C5, IFNG, TERT | DPP4 1318/4885DPP8 3189/4885DPP9 2218/4885 |
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | DPP4 1543/4885DPP8 675/4885DPP9 488/4885 |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | DPP4 1573/4885DPP8 1130/4885DPP9 676/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | DPP4 603/4885DPP8 480/4885DPP9 493/4885 |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | DPP4 1045/4885DPP8 1418/4885DPP9 1373/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | DPP4 1889/4885DPP8 948/4885DPP9 1346/4885 |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | DPP4 1230/4885DPP8 950/4885DPP9 1018/4885 |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | DPP4 1230/4885DPP8 950/4885DPP9 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.